Lilly to Acquire Merida in $2.875B Immunology Deal

Indianapolis, Indiana, and Cambridge, Massachusetts, August 31, 2026

Merida Brings Precision Autoantibody Approach

Merida is developing a new therapeutic approach focused on pathogenic autoantibodies, which can drive a range of immune-mediated diseases. Its antibody-engineering platform is designed to enable the precise and durable degradation of disease-causing antibodies, rather than broadly suppressing immune activity. This distinction could be important in autoimmune and allergic conditions because many existing therapies work by reducing immune-system activity more generally. Merida’s lead program, MER511, is currently being evaluated in a Phase 1 clinical trial for Graves’ disease and thyroid eye disease (TED). Both conditions are associated with thyroid-stimulating immunoglobulins, a type of pathogenic autoantibody that activates the thyroid-stimulating hormone receptor. According to the companies, initial Phase 1 data showed robust reductions in pathogenic thyroid-stimulating antibodies together with a favorable initial safety profile. The scientific rationale behind MER511 is to directly address the antibodies responsible for disease rather than treating only downstream consequences. Lilly said the approach could potentially be applied across a broader range of antibody-driven diseases, giving the acquisition significance beyond Merida’s current lead indication.

Pipeline Expands Across Autoimmune and Allergic Diseases

Beyond MER511, Merida has additional programs exploring the potential of its precision antibody-degradation technology. Its MER769 program is in preclinical development for food allergy, asthma and chronic spontaneous urticaria, as well as other diseases involving antibodies responsible for triggering allergic reactions. Earlier-stage research programs are also focused on kidney diseases, including membranous nephropathy, and other immune-mediated conditions. The acquisition therefore gives Lilly access not only to a single investigational therapy but also to a broader platform technology that could potentially generate multiple precision immunology treatments. This platform-based opportunity aligns with Lilly’s strategy of expanding its pipeline through biotechnology acquisitions and strengthening its capabilities in areas with substantial unmet medical need. For patients with serious autoimmune and allergic diseases, the potential advantage of selectively removing pathogenic antibodies could be significant if the approach ultimately demonstrates durable disease control while maintaining normal immune function. However, MER511 remains investigational, and the available clinical evidence is still early-stage. Further clinical trials will be required to establish its efficacy and safety across specific diseases.

$2.875 Billion Deal Targets Immunology Growth

Under the terms announced by the companies, Lilly will pay up to $2.875 billion in cash, consisting of an upfront payment and contingent milestone payments. The transaction remains subject to customary closing conditions, including applicable regulatory approvals, and is expected to close in the fourth quarter of 2026. For Lilly, the agreement represents another major business-development investment in immunology, adding a precision approach to its efforts to develop treatments for immune-mediated diseases. The company has been expanding its research portfolio through acquisitions and partnerships across several therapeutic areas, with immunology representing an important component of its broader pipeline strategy. The Merida acquisition also highlights the growing interest in disease-modifying approaches to autoimmune disorders. Rather than broadly suppressing immune responses, targeted elimination of pathogenic antibodies seeks to intervene closer to the biological drivers of disease. If Merida’s technology can translate its early findings into meaningful clinical benefits, it could potentially support a new generation of precision therapies across multiple autoimmune and allergic conditions. For now, the transaction marks a significant M&A milestone in biopharma, while the clinical development of MER511 and Merida’s broader platform will determine the ultimate therapeutic value of the acquisition. Lilly’s planned integration of Merida is expected to provide additional resources and development capabilities as the companies work toward advancing these investigational treatments.

Source: Eli Lilly, Merida Biosciences press relese